Interview: Orchard's Gene Therapies Bear Fruit With $110m Financing

The UK firm has attracted more top-tier investors who are clearly impressed with its gene therapy for bubble baby syndrome and a high-quality pipeline in other very rare diseases.

Apples
Pick of the crop: Orchard has quickly become a main player in gene therapy • Source: Shutterstock

The desire of the UK's Orchard Therapeutics to become a key player globally in the gene therapy space has received a major boost this morning (Dec. 20) with the completion of an oversubscribed $110m financing, backed by powerhouse healthcare investors.

"It is a serious fundraise," CEO Mark Rothera told Scrip in an interview, and the Series B round, co-led by Baillie Gifford and ORI Capital, has attracted significant new investments from Singapore's Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital and 4BIO Capital, as well as existing investors F-Prime Capital and UCL Technology Fund

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

More from Scrip

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By 

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By 

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.